Literature DB >> 26191301

Epithelioid inflammatory myofibroblastic sarcoma with recurrence after extensive resection: significant clinicopathologic characteristics of a rare aggressive soft tissue neoplasm.

Jun Zhou1, Guozhong Jiang1, Dandan Zhang1, Lan Zhang1, Jingjing Xu1, Shenglei Li1, Wencai Li1, Yihui Ma1, Ahong Zhao1, Zhihua Zhao1.   

Abstract

A case of epithelioid inflammatory myofibroblastic scarcoma (EIMS) developing in an 8-year-old boy who presented with a bulky intra-abdominal occupying lesion with recurrence undergoing a radical resection was reported. Histologically, the tumor cells arranged in cords, strands or sheets of round-to-epithelioid cells with a vesicular nuclear chromatin pattern, prominent nucleoli and weakly eosinophic or basophilic cytoplasm embedded in the abundant myxoid stroma with lymphocytes infiltration. They were positive for ALK, Desmin, SMA, CD30, but negative for AE1/AE3, LCA, CD2, CD3, CD5, CD7, S-100, CD34, CD31, EMA, MyoD1, and myogenin. An elevated proliferation index was demonstrated by Ki-67 comparing the first and the second lesion. Fluorescence in situ (FISH) showed the presence of chromosomal translocation involving ALK. This case show EIMS is a rare variant of inflammatory myofibroblatic tumor with aggressive biological behavior and unfavourable prognosis. To be familiar with its significant clinicopathologic characteristics could prompt us to take it into consideration when facing the relevant dieases.

Entities:  

Keywords:  ALK; Epithelioid inflammatory myofibroblastic scarcoma; FISH; soft tissue neoplasm

Mesh:

Substances:

Year:  2015        PMID: 26191301      PMCID: PMC4503172     

Source DB:  PubMed          Journal:  Int J Clin Exp Pathol        ISSN: 1936-2625


  8 in total

1.  Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor.

Authors:  James E Butrynski; David R D'Adamo; Jason L Hornick; Paola Dal Cin; Cristina R Antonescu; Suresh C Jhanwar; Marc Ladanyi; Marzia Capelletti; Scott J Rodig; Nikhil Ramaiya; Eunice L Kwak; Jeffrey W Clark; Keith D Wilner; James G Christensen; Pasi A Jänne; Robert G Maki; George D Demetri; Geoffrey I Shapiro
Journal:  N Engl J Med       Date:  2010-10-28       Impact factor: 91.245

2.  A case report of epithelioid inflammatory myofibroblastic sarcoma with RANBP2-ALK fusion gene treated with the ALK inhibitor, crizotinib.

Authors:  Shiro Kimbara; Koji Takeda; Hiroko Fukushima; Toru Inoue; Hideaki Okada; Yumi Shibata; Utae Katsushima; Asuka Tsuya; Shinya Tokunaga; Haruko Daga; Takahiro Okuno; Takeshi Inoue
Journal:  Jpn J Clin Oncol       Date:  2014-07-15       Impact factor: 3.019

3.  ALK inhibition for the treatment of refractory epithelioid inflammatory myofibroblastic sarcoma.

Authors:  Mikihiro Fujiya; Yutaka Kohgo
Journal:  Intern Med       Date:  2014       Impact factor: 1.271

4.  Epithelioid inflammatory myofibroblastic sarcoma: An aggressive intra-abdominal variant of inflammatory myofibroblastic tumor with nuclear membrane or perinuclear ALK.

Authors:  Adrián Mariño-Enríquez; Wei-Lien Wang; Angshumoy Roy; Dolores Lopez-Terrada; Alexander J F Lazar; Christopher D M Fletcher; Cheryl M Coffin; Jason L Hornick
Journal:  Am J Surg Pathol       Date:  2011-01       Impact factor: 6.394

5.  Colonic inflammatory myofibroblastic tumours: an institutional review.

Authors:  R K Gupta; N E Samalavicius; S Sapkota; P L Sah; S U Kafle
Journal:  Colorectal Dis       Date:  2013-05       Impact factor: 3.788

6.  Epithelioid inflammatory myofibroblastic sarcoma arising in the pleural cavity.

Authors:  Yoshiki Kozu; Mitsuhiro Isaka; Yasuhisa Ohde; Kengo Takeuchi; Takashi Nakajima
Journal:  Gen Thorac Cardiovasc Surg       Date:  2013-01-24

7.  Inflammatory myofibroblastic tumors harbor multiple potentially actionable kinase fusions.

Authors:  Christine M Lovly; Abha Gupta; Doron Lipson; Geoff Otto; Tina Brennan; Catherine T Chung; Scott C Borinstein; Jeffrey S Ross; Philip J Stephens; Vincent A Miller; Cheryl M Coffin
Journal:  Cancer Discov       Date:  2014-05-29       Impact factor: 39.397

Review 8.  Inflammatory myofibroblastic tumor with RANBP2 and ALK gene rearrangement: a report of two cases and literature review.

Authors:  Jian Li; Wei-hua Yin; Kengo Takeuchi; Hong Guan; Yu-hua Huang; John K C Chan
Journal:  Diagn Pathol       Date:  2013-09-13       Impact factor: 2.644

  8 in total
  5 in total

1.  Clinicopathological analysis of epithelioid inflammatory myofibroblastic sarcoma.

Authors:  Xuemei Du; Ying Gao; Hongyu Zhao; Bin Li; Weimin Xue; Daye Wang
Journal:  Oncol Lett       Date:  2018-04-18       Impact factor: 2.967

Review 2.  Epithelioid inflammatory myofibroblastic sarcoma with VCL-ALK fusion of central nervous system: case report and brief review of the literature.

Authors:  Shefali Chopra; Nolan Maloney; Wei Lien Wang
Journal:  Brain Tumor Pathol       Date:  2021-11-06       Impact factor: 3.298

Review 3.  Epithelioid inflammatory myofibroblastic sarcoma treated with ALK inhibitor: a case report and review of literature.

Authors:  Qiuyu Liu; Yunzhen Kan; Yuewu Zhao; Hui He; Lingfei Kong
Journal:  Int J Clin Exp Pathol       Date:  2015-11-01

4.  CD30 and ALK combination therapy has high therapeutic potency in RANBP2-ALK-rearranged epithelioid inflammatory myofibroblastic sarcoma.

Authors:  Karen L MacKenzie; Toby N Trahair; Ashleigh M Fordham; Jinhan Xie; Andrew J Gifford; Carol Wadham; Lisa T Morgan; Emily V A Mould; Mitali Fadia; Lei Zhai; Hassina Massudi; Zara S Ali; Glenn M Marshall; Robyn E Lukeis; Jamie I Fletcher
Journal:  Br J Cancer       Date:  2020-07-20       Impact factor: 7.640

5.  Incomplete Intestinal Obstruction Caused by a Rare Epithelioid Inflammatory Myofibroblastic Sarcoma of the Colon: A Case Report.

Authors:  Yanjun Bai; Maofen Jiang; Wenjie Liang; Feng Chen
Journal:  Medicine (Baltimore)       Date:  2015-12       Impact factor: 1.817

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.